Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Clinical trial NCT07162181 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07162181
Sponsor: Eli Lilly and Company
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell B-cell Lymphoma

Start date: 2025-08-07
Primary completion: 2030-05-01
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.